Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Axitinib · Inlyta

Small molecule · Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4) · developed by Pf Prism Cv

Approved FDA, Jan 2012

What is Axitinib?

Axitinib is a kinase inhibitor that blocks vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3, inhibiting VEGF-mediated endothelial cell proliferation and survival and tumor angiogenesis. It is studied in advanced malignancies, non-small cell lung cancer, ovarian cancer, urothelial cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Inlyta
Drug type
Small molecule
Targets
VEGFR-1 (FLT1), VEGFR-2 (KDR), VEGFR-3 (FLT4)
Mechanism
Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4)
Pathways
VEGF-mediated angiogenesis, endothelial cell proliferation and survival
Therapy area
Oncology
Developer
Pf Prism Cv
In trials of
PFE
FDA status
Approved as Inlyta (January 27, 2012), NDA202324 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 12, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer

Other drugs acting on FLT1 / KDR / FLT4

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.